Tranbit is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
Tenofovir alafenamide is a phosphonamidate prodrug of tenofovir (2’-deoxyadenosine monophosphate analog). Tenofovir alafenamide as a lipophilic cell-permeant compound enters primary hepatocytes by passive diffusion and by the hepatic uptake transporters OATP1B1 and OATP1B3. Tenofovir alafenamide is then converted to tenofovir through hydrolysis primarily by carboxylesterase 1 (CES1) in primary hepatocytes. Intracellular tenofovir is subsequently phosphorylated by cellular kinases to the pharmacologically active metabolite tenofovir diphosphate. Tenofovir diphosphate inhibits HBV replication through incorporation into viral DNA by the HBV reverse transcriptase, which results in DNA chain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase γ and there is no evidence of toxicity to mitochondria in cell culture.
Testing Prior to Initiation of Tenofovir alafenamide : Prior to initiation of Tenofovir alafenamide, patients should be tested for HIV-1 infection. Tenofovir alafenamide alone should not be used in patients with HIV-1 infection. Recommended Dosage in Adults : The recommended dosage of Tenofovir alafenamide is 25 mg (one tablet) taken orally once daily with food. Dosage in Patients with Renal Impairment : No dosage adjustment of Tenofovir alafenamide is required in patients with estimated creatinine clearance greater than or equal to 15 ml per minute or in patients with end stage renal disease (ESRD; estimated creatinine clearance below 15 ml per minute) who are receiving chronic hemodialysis. On days of hemodialysis administer Tenofovir alafenamide after completion of hemodialysis treatment. Tenofovir alafenamide is not recommended in patients with ESRD who are not receiving chronic hemodialysis. Dosage in Patients with Hepatic Impairment : No dosage adjustment of Tenofovir alafenamide is required in patients with mild hepatic impairment (Child-Pugh A). Tenofovir alafenamide is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment. Pediatric Use : Safety and effectiveness of Tenofovir alafenamide in pediatric patients less than 18 years of age have not been established. Geriatric Use : In clinical trials, Tenofovir alafenamide was administered to 89 subjects aged 65 and over. No clinically significant differences in safety or efficacy have been observed between elderly subjects and subjects between 18 and less than 65 years of age.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
The following adverse reactions are discussed in other sections of the labeling: Lactic Acidosis/Severe Hepatomegaly with Steatosis Severe Acute Exacerbation of Hepatitis B New Onset or Worsening of Renal Impairment The most common side effects are headache, stomach pain, tiredness, cough, nausea, back pain
Potential for Other Drugs to Affect Tranbit : Tranbit is a substrate of P-glycoprotein (P-gp) and BCRP. Drugs that strongly affect P-gp and BCRP activity may lead to changes in Tranbit absorption. Drugs that induce P-gp activity are expected to decrease the absorption of Tranbit resulting in decreased plasma concentrations of Tranbit which may lead to loss of therapeutic effect of Tranbit. Coadministration of Tranbit with other drugs that inhibit P-gp and BCRP may increase the absorption & plasma concentration of Tranbit. Drugs Affecting Renal Function : Tranbit is primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion, coadministration of Tranbit with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs and this may increase the risk of adverse reactions. Some examples of drugs that are eliminated by active tubular secretion include but are not limited to acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin) and high-dose or multiple NSAIDs.
Severe Acute Exacerbation of Hepatitis B after Discontinuation of Treatment : Discontinuation of anti-hepatitis B therapy, including Tranbit may result in severe acute exacerbations of hepatitis B. Patients who discontinue Tranbit should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. If appropriate resumption of antihepatitis B therapy may be warranted. Risk of Development of HIV-1 Resistance in Patients Coinfected with HBV and HIV-1 : Due to the risk of development of HIV-1 resistance Tranbit alone is not recommended for the treatment of HIV-1 infection. The safety and efficacy of Tranbit have not been established in patients coinfected with HBV and HIV-1. HIV antibody testing should be offered to all HBV-infected patients before initiating therapy with Tranbit and if positive, an appropriate antiretroviral combination regimen that is recommended for patients coinfected with HIV-1 should be used. New Onset or Worsening Renal Impairment : Postmarketing cases of renal impairment, including acute renal failure, proximal renal tubulopathy (PRT) and Fanconi syndrome have been reported with TAF-containing products; while most of these cases were characterized by potential confounders that may have contributed to the reported renal events, it is also possible these factors may have predisposed patients to tenofovir- related adverse events. Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents, including non-steroidal anti-inflammatory drugs, are at increased risk of developing renal-related adverse reactions. Prior to or when initiating Tranbit and during treatment with Tranbit on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus. Discontinue Tranbit in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome. Lactic Acidosis/Severe Hepatomegaly with Steatosis : Lactic acidosis and severe hepatomegaly with steatosis including fatal cases have been reported with the use of nucleoside analogs including tenofovir disoproxil fumarate (TDF) another prodrug of tenofovir alone or in combination with other antiretrovirals. Treatment with Tranbit should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).